Table 1 |
||||||
|
Summary of trials of erythropoietin in acutely critically ill patients |
||||||
|
Year |
Reference |
ntotal |
nsepsis |
Enrolment |
Dose |
Duration |
|
|
||||||
|
1995 |
Still and colleagues [96] |
40 |
0 |
> 3 days |
150 IU/kg three times/week |
30 days |
|
1998 |
Gabriel and colleagues [93] |
21 |
ns |
ICU admission |
600 IU/kg three times/week |
Maximum 3 weeks |
|
1999 |
Corwin and colleagues [92] |
80 |
6 |
Day 3 |
300 IU/kg daily for 5 days |
Maximum 6 weeks |
|
2000 |
van Iperen and colleagues [97] |
36 |
23 |
Hb < 11.2 g/dl |
300 IU/kg alternate days for 5 days |
5 doses |
|
2002 |
Corwin and colleagues [87] |
1,352 |
105 |
Day 3 |
40,000 IU/week |
Maximum 3 weeks |
|
2005 |
Georgopoulos and colleagues [94] |
148 |
ns |
Hb < 12.0 g/dl |
40,000 IU/week |
Maximum 3 weeks |
|
2006 |
Vincent and colleagues [84] |
68 |
14 |
HCT < 0.38 |
40,000 IU/week |
Maximum 4 weeks |
|
2006 |
Silver and colleagues [95] |
86 |
25 |
< 7 days |
40,000 IU/week |
Maximum 12 weeks |
|
2007 |
Corwin and colleagues [88] |
1,460 |
188 |
Day 3/4 |
40,000 U/week |
Maximum 3 weeks |
|
|
||||||
|
Number of patients with sepsis is shown and the timing of erythropoietin use. Hb, haemoglobin; HCT, haematocrit; ICU, intensive care unit; ns, not specified. |
||||||
|
Walden et al. Critical Care 2010 14:227 doi:10.1186/cc9049 |
||||||